Abera Bioscience AB (FRA:8WK)

Market Cap	12.41M +33.2%
Revenue (ttm)	821.47K -42.2%
Net Income	-1.90M
EPS	-0.10
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	60
Open	0.5420
Previous Close	0.5460
Day's Range	0.5420 - 0.6080
52-Week Range	0.4440 - 0.8380
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 13, 2026

About Abera Bioscience AB

Abera Bioscience AB, a platform and vaccine development company, develops vaccines based on its proprietary and patented platform in Sweden and internationally. The company’s development platform named BERA, uses for the display of antigens at the surface of outer membrane vesicles derived from genetically optimized gram-negative bacteria. Its lead vaccine candidate is a universal pneumococcal vaccine. The company also develops projects in Flu, Diarrhea Chlamydia, ETEC, Covid-19, and Tuberculosis. The company was incorporated in 2012 and is hea...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 6
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 8WK

Financial Performance

In 2025, Abera Bioscience AB's revenue was 11.85 million, a decrease of -18.99% compared to the previous year's 14.63 million. Losses were -10.45 million, 850.3% more than in 2024.

Financial numbers in SEK

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Oct 26, 2026

Data Sources Report a data error